Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG
Your view on SPHDF
Overview
What the company does, where it operates, and who runs it.
About Santhera Pharmaceuticals Holding AG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dario Eklund
- Headquarters
- Hohenrainstrasse 24, Pratteln, CH
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dario Eklund
- Headquarters
- Hohenrainstrasse 24, Pratteln, CH
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally.
The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies.
The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Santhera Pharmaceuticals Holding AG, and the rating behind it. SPHDF last traded at $21.15; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Santhera Pharmaceuticals Holding AG. Starting points for Santhera Pharmaceuticals Holding AG: EPS -$3.68, beta -0.72 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Santhera Pharmaceuticals Holding AG. Santhera Pharmaceuticals Holding AG does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Santhera Pharmaceuticals Holding AG. Trailing twelve-month EPS for Santhera Pharmaceuticals Holding AG stands at -$3.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Santhera Pharmaceuticals Holding AG. Santhera Pharmaceuticals Holding AG has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Santhera Pharmaceuticals Holding AG valued side by side against its closest peers. Santhera Pharmaceuticals Holding AG is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Santhera Pharmaceuticals Holding AG, and how their positions are changing. At a $294.9M market value, institutional positions materially move Santhera Pharmaceuticals Holding AG's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Santhera Pharmaceuticals Holding AG executives and directors. Shares of Santhera Pharmaceuticals Holding AG have traded between $9.42 and $22.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Santhera Pharmaceuticals Holding AG. Santhera Pharmaceuticals Holding AG is a $294.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Santhera Pharmaceuticals Holding AG. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Santhera Pharmaceuticals Holding AG. Coverage tracks Santhera Pharmaceuticals Holding AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.